abstract: The antitumor effects of @entity9 ( @entity9 ), @entity5 ( @entity5 ) and @entity3 ( @entity4 ), administered separately or in various combinations, on @entity0 @entity1 cells xenotransplanted into BALB/c @entity2 were studied using the protocol of Battelle's Columbus Laboratories (Ovejera et al., 1978). @entity9 (1,000 mg/kg in 2 divided doses) and @entity5 (50 mg/kg) were given intraperitoneally (i.p.) for 7 consecutive days from the time when the @entity1 weighed about 100 mg. @entity4 (2 mg/kg) was given i.p. every other day from the same time. Animals treated with either @entity9 or @entity5 alone displayed @entity1 growth comparable to that seen in untreated controls. In @entity2 treated with @entity9 plus @entity5 with or without @entity4 , or in @entity2 treated only with @entity4 , @entity1 growth was significantly lower than in untreated @entity2 . In the group which received only combined @entity9 / @entity5 there was a rapid regrowth of the @entity1 after termination of therapy. @entity1 putrescine levels decreased within 4 days following the administration of @entity9 ; however, @entity8 levels did not decline with either @entity9 or @entity5 treatment even after 7 days. When combined @entity9 / @entity5 was given, there was a significant decline in @entity8 levels 7 days after the initiation of treatment. In contrast, when @entity4 alone was administered, @entity6 and @entity8 levels in the @entity1 did not differ from those in control @entity2 . @entity7 decreased markedly in @entity1 with the combined administration of @entity9 / @entity5 as well as with combined @entity9 / @entity5 / @entity4 , but decreased only slightly when @entity4 alone or @entity4 plus either @entity9 or @entity5 was administered. By the 7th treatment day, DNA biosynthesis in the @entity1 had dropped markedly in all groups except those receiving @entity9 or @entity5 alone.
  